{"id":"W4409052291","doi":"10.1016/j.ejca.2025.115397","title":"Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study","year":2025,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"Memorial Sloan-Kettering Cancer Center; Genentech Foundation","keywords":"Fulvestrant; Metastatic breast cancer; Letrozole; HER2 negative; Oncology; Medicine; Breast cancer; Internal medicine; Maximum tolerated dose; Cancer; Estrogen receptor; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001444805,0.001492434,0.001840398,0.0006778541,0.0003315851,0.0008848622,0.0009421092,0.0007873249,0.002715901],"category_scores_gemma":[0.0005928944,0.0005528047,0.001128524,0.000482858,0.001013566,0.0007722394,0.0003785973,0.002604089,0.0006918196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001003875,"about_ca_system_score_gemma":0.001688127,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001364331,"about_ca_topic_score_gemma":0.003517957,"domain_scores_codex":[0.9995723,0.00017276,0.00002486142,0.00007172755,0.00006097694,0.00009727105],"domain_scores_gemma":[0.9995155,0.00006907855,0.0001050608,0.00005008835,0.00002937827,0.0002308126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6652236,0.1378173,0.005842633,0.001036218,0.001440705,0.0002512176,0.0003657973,0.002918866,0.07285314,0.0002227222,0.002226571,0.1098012],"study_design_scores_gemma":[0.3124849,0.6676169,0.01064572,0.00004137893,0.0005340158,0.0002180582,0.00007248784,0.0007157833,0.005379832,0.0001329871,0.002126247,0.00003157803],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963398,0.001280375,0.0001986457,0.0001130628,0.00003480969,0.0008240291,0.0004514571,0.00005021237,0.0007076887],"genre_scores_gemma":[0.9917963,0.002110323,0.0008711577,0.0004010875,0.00009368365,0.001120909,0.00157286,0.00002604206,0.002007769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002715901,"threshold_uncertainty_score":0.009085655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03895608083333525,"score_gpt":0.3902829151311198,"score_spread":0.3513268342977846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}